Physician profile
Michael E Carlos
NPI 1760473110
$2,666.36
in general payments reported to CMS, 2019-2025
29 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $145 · 2021: $76.20 · 2022: $176 · 2023: $357 · 2024: $419 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,502.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $427.37 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $351.28 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $270.21 | 2019-2025 | |
| Pfizer INC. | $248.24 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $189.05 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $171.23 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $158.36 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.38 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $113.87 | 2024-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $92.18 | 2023-2024 | Onpattro |
| Merck Sharp & Dohme LLC | $84.73 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $52.21 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.31 | 2023-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $42.78 | 2019 | |
| Boston Scientific Corporation | $27.74 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $22.04 | 2019 | |
| Medtronic Vascular, INC. | $21.58 | 2020 | |
| Vivus LLC | $20.83 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.57 | 2025 | |
| Heartflow, INC. | $19.54 | 2025 | |
| Medtronic, INC. | $19.51 | 2023 | Linq II |
| Braemar Manufacturing, LLC | $18.90 | 2019 | |
| Glaxosmithkline, LLC. | $16.49 | 2025 | Shingrix |
| Lilly USA, LLC | $16.33 | 2019 | |
| Scpharmaceuticals INC. | $16.26 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.74 | 2023 | Evkeeza |
| Cranial Technologies, INC | $14.95 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.46 | 2023 | Inpefa |
| Currax Pharmaceuticals LLC | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Carlos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.